NASDAQ:FLGT

Fulgent Genetics Competitors

$70.02
+1.55 (+2.26 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$62.50
$70.59
50-Day Range
$68.47
$109.78
52-Week Range
$13.40
$189.89
Volume1.16 million shs
Average Volume1.84 million shs
Market Capitalization$2.03 billion
P/E Ratio34.66
Dividend YieldN/A
Beta1.92

Competitors

Fulgent Genetics (NASDAQ:FLGT) Vs. NTRA, NVTA, CDNA, BNR, VCYT, and GTH

Should you be buying FLGT stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Fulgent Genetics, including Natera (NTRA), Invitae (NVTA), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), and Genetron (GTH).

Natera (NASDAQ:NTRA) and Fulgent Genetics (NASDAQ:FLGT) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Earnings and Valuation

This table compares Natera and Fulgent Genetics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$302.33 million26.16$-124,830,000.00($1.99)-45.35
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00

Fulgent Genetics has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Natera and Fulgent Genetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natera01902.90
Fulgent Genetics12202.20

Natera currently has a consensus price target of $114.70, suggesting a potential upside of 27.09%. Fulgent Genetics has a consensus price target of $74.40, suggesting a potential upside of 6.26%. Given Natera's stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Fulgent Genetics.

Profitability

This table compares Natera and Fulgent Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natera-52.11%-53.39%-25.89%
Fulgent Genetics35.31%43.81%36.82%

Risk & Volatility

Natera has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.

Institutional & Insider Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 33.4% of Fulgent Genetics shares are held by institutional investors. 9.3% of Natera shares are held by insiders. Comparatively, 45.0% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Natera on 9 of the 14 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Fulgent Genetics (NASDAQ:FLGT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Institutional and Insider Ownership

78.6% of Invitae shares are held by institutional investors. Comparatively, 33.4% of Fulgent Genetics shares are held by institutional investors. 2.9% of Invitae shares are held by company insiders. Comparatively, 45.0% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Invitae and Fulgent Genetics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$216.82 million25.79$-241,960,000.00($2.28)-12.27
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00

Fulgent Genetics has lower revenue, but higher earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Invitae and Fulgent Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invitae-183.50%-81.19%-37.28%
Fulgent Genetics35.31%43.81%36.82%

Volatility and Risk

Invitae has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Invitae and Fulgent Genetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invitae03402.57
Fulgent Genetics12202.20

Invitae presently has a consensus target price of $46.1667, suggesting a potential upside of 65.00%. Fulgent Genetics has a consensus target price of $74.40, suggesting a potential upside of 6.26%. Given Invitae's stronger consensus rating and higher possible upside, analysts plainly believe Invitae is more favorable than Fulgent Genetics.

Summary

Fulgent Genetics beats Invitae on 8 of the 14 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and CareDx (NASDAQ:CDNA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares Fulgent Genetics and CareDx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
CareDx-11.79%-10.95%-7.94%

Institutional & Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by company insiders. Comparatively, 3.1% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Fulgent Genetics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, CareDx has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fulgent Genetics and CareDx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
CareDx01413.00

Fulgent Genetics presently has a consensus target price of $74.40, suggesting a potential upside of 6.26%. CareDx has a consensus target price of $75.6667, suggesting a potential upside of 15.08%. Given CareDx's stronger consensus rating and higher probable upside, analysts plainly believe CareDx is more favorable than Fulgent Genetics.

Valuation & Earnings

This table compares Fulgent Genetics and CareDx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00
CareDx$127.07 million26.93$-21,970,000.00($0.52)-126.44

Fulgent Genetics has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Fulgent Genetics beats CareDx on 10 of the 15 factors compared between the two stocks.

Burning Rock Biotech (NASDAQ:BNR) and Fulgent Genetics (NASDAQ:FLGT) are both mid-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

15.8% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 33.4% of Fulgent Genetics shares are owned by institutional investors. 45.0% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Burning Rock Biotech and Fulgent Genetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock BiotechN/AN/AN/AN/AN/A
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00

Burning Rock Biotech has higher earnings, but lower revenue than Fulgent Genetics.

Profitability

This table compares Burning Rock Biotech and Fulgent Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burning Rock BiotechN/AN/AN/A
Fulgent Genetics35.31%43.81%36.82%

Analyst Ratings

This is a summary of recent ratings and price targets for Burning Rock Biotech and Fulgent Genetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burning Rock Biotech00303.00
Fulgent Genetics12202.20

Burning Rock Biotech presently has a consensus target price of $32.30, suggesting a potential upside of 23.57%. Fulgent Genetics has a consensus target price of $74.40, suggesting a potential upside of 6.26%. Given Burning Rock Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Burning Rock Biotech is more favorable than Fulgent Genetics.

Summary

Fulgent Genetics beats Burning Rock Biotech on 6 of the 9 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Risk and Volatility

Fulgent Genetics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Insider & Institutional Ownership

33.4% of Fulgent Genetics shares are owned by institutional investors. 45.0% of Fulgent Genetics shares are owned by insiders. Comparatively, 8.3% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Fulgent Genetics and Veracyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
Veracyte11602.63

Fulgent Genetics currently has a consensus target price of $74.40, suggesting a potential upside of 6.26%. Veracyte has a consensus target price of $58.4286, suggesting a potential upside of 46.47%. Given Veracyte's stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Fulgent Genetics.

Earnings and Valuation

This table compares Fulgent Genetics and Veracyte's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00
Veracyte$120.37 million22.28$-12,600,000.00($0.27)-147.74

Fulgent Genetics has higher earnings, but lower revenue than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fulgent Genetics and Veracyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
Veracyte-30.46%-12.27%-10.95%

Summary

Fulgent Genetics beats Veracyte on 10 of the 14 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Fulgent Genetics and Genetron, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
Genetron00203.00

Fulgent Genetics currently has a consensus target price of $74.40, suggesting a potential upside of 6.26%. Genetron has a consensus target price of $19.50, suggesting a potential upside of 7.68%. Given Genetron's stronger consensus rating and higher probable upside, analysts clearly believe Genetron is more favorable than Fulgent Genetics.

Profitability

This table compares Fulgent Genetics and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
GenetronN/AN/AN/A

Insider and Institutional Ownership

33.4% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 19.6% of Genetron shares are owned by institutional investors. 45.0% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Fulgent Genetics and Genetron's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00
Genetron$45.68 million35.23$-95,470,000.00N/AN/A

Fulgent Genetics has higher earnings, but lower revenue than Genetron.

Summary

Fulgent Genetics beats Genetron on 7 of the 10 factors compared between the two stocks.


Fulgent Genetics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Natera logo
NTRA
Natera
1.7$90.25+0.4%$7.91 billion$302.33 million-37.92Earnings Announcement
Analyst Report
Invitae logo
NVTA
Invitae
1.6$27.98+3.2%$5.59 billion$216.82 million-7.19Earnings Announcement
Analyst Report
Gap Down
CareDx logo
CDNA
CareDx
1.2$65.75+1.4%$3.42 billion$127.07 million-142.93Earnings Announcement
Gap Down
BNR
Burning Rock Biotech
1.1$26.14+0.0%$2.73 billionN/A0.00
Veracyte logo
VCYT
Veracyte
1.4$39.89+6.1%$2.68 billion$120.37 million-57.81Earnings Announcement
Analyst Report
News Coverage
Gap Down
GTH
Genetron
0.4$18.11+4.3%$1.61 billion$45.68 million0.00News Coverage
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$54.56+0.4%$1.37 billion$51.87 million-320.92Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
RadNet logo
RDNT
RadNet
1.3$23.96+4.8%$1.25 billion$1.15 billion-114.09Earnings Announcement
News Coverage
Renalytix AI logo
RNLX
Renalytix AI
0.7$27.61+5.0%$994.62 millionN/A-172.56Gap Down
DermTech logo
DMTK
DermTech
1.6$33.27+4.6%$961.70 million$3.36 million-19.69Upcoming Earnings
Analyst Report
Gap Down
Personalis logo
PSNL
Personalis
1.6$19.46+0.2%$854.45 million$65.21 million-18.36Earnings Announcement
Analyst Revision
Gap Down
Celcuity logo
CELC
Celcuity
1.0$25.92+2.9%$318.51 millionN/A-30.49Earnings Announcement
Upcoming Earnings
News Coverage
Exagen logo
XGN
Exagen
1.7$15.06+0.7%$190.81 million$40.39 million-1.23Gap Down
Centogene logo
CNTG
Centogene
1.2$9.05+0.3%$179.74 million$54.64 million-6.20
Progenity logo
PROG
Progenity
1.8$2.50+6.0%$150.86 millionN/A0.00Upcoming Earnings
News Coverage
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.96+1.4%$142.76 million$76.02 million-6.88Gap Down
OpGen logo
OPGN
OpGen
1.3$2.27+1.8%$86.86 million$3.50 million-1.12Upcoming Earnings
Gap Down
Biocept logo
BIOC
Biocept
1.2$4.68+4.5%$62.73 million$5.53 million-1.16Upcoming Earnings
Gap Down
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$4.41+1.8%$49.40 million$1.56 million-2.72Upcoming Earnings
Gap Down
Psychemedics logo
PMD
Psychemedics
0.8$6.66+5.7%$36.87 million$37.68 million-9.65News Coverage
AMS
American Shared Hospital Services
0.1$2.76+1.4%$16.01 million$20.60 million-27.60High Trading Volume
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.